Skip to main content
OpenTrials
Completed

NCT Number: NCT04015908

A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery

The primary objective of this trial is to determine whether the combination of three non-opioid analgesics (multimodal analgesia) can significantly reduce or eliminate the need for opioids after ambulatory surgery.

A secondary objective would be to present credible data for insurance providers about the opioid sparing effect of these medications. This data may encourage insurance providers to support payment for short term use of certain analgesics that currently require prior authorization.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Utah

Salt Lake City, Utah, 84112, United States

About this study

Prescription opioids are associated with addiction and accidental overdose, yet they continue to be the most commonly prescribed analgesics after ambulatory surgery.

Multimodal analgesia is a promising alternative to opioids. It is based on the theory that a combination of more than one analgesic (with non-opioid mechanisms of action) can provide pain relief equal to or exceeding that of traditional opioids.

Multimodal analgesia is not associated with opioid related side effects such as respiratory depression, nausea, constipation, and itching.

Implementation of multi-modal analgesia in an ambulatory setting is challenging for a number of reasons.

First, patient compliance with multiple medications and complex dosing schedules is poor.

Second, misinformation still exists about the dosing of acetaminophen and NSAIDS (non-steroidal anti-inflammatory drugs). For example, many patients and health care providers believe that acetaminophen and NSAIDS cannot be taken concurrently. As a result, the additive analgesic effect of combining these drugs is not achieved.

Finally, some medications used for multimodal analgesia can be difficult to procure in the ambulatory setting. For example, pregabalin (trade name Lyrica) has been used successfully to treat acute pain and reduce opioid requirements after surgery. However, its mechanism of action is similar to that of gabapentin (an older and less expensive drug) and insurers are reluctant to approve its use over the expensive alternative.

Although gabapentin is a useful analgesic for chronic pain, its delayed onset of activity and unpredictable blood levels after oral administration make it impractical to use in the setting of acute pain. In fact, optimal dosing of gabapentin may require several days or weeks to establish.By contrast, pregabalin has a rapid onset of action with consistent and predictable plasma levels after oral administration.

For this trial, patients in the control group would receive traditional postoperative pain medication consisting of a combination of oxycodone and acetaminophen (trade name Percocet) as needed at 4-6 hour intervals.

Patients in the study group would receive the following:

  • Three non-opioid pain medications (acetaminophen,celecoxib, and pregabalin) would be taken concurrently at six hour intervals for a period of 7 days.
  • These three non-opioid medications (acetaminophen, celecoxib, and pregabalin ) would be provided in a "blister pack". All scheduled pain medication for a given 6 hour interval would be contained in a single compartment to simplify compliance for the patient. Study patients would also have access to oxycodone as a "rescue medication".

The principles of postoperative pain management addressed in this protocol are supported by existing literature.

  • Patient compliance with complex medication dosing protocols may be improved using calender and time based "blister packs".
  • Pain control using combined acetaminophen and NSAID is superior to that either drug in isolation
  • Pregabalin can reduce opioid requirements and opioid related nausea when treating acute pain.

The primary objective of this trial is to determine whether the combination of three non-opioid analgesics (multimodal analgesia) can significantly reduce or eliminate the need for opioids after ambulatory surgery.

A secondary objective would be to present credible data for insurance providers about the opioid sparing effect of these medications. This data may encourage insurance providers to support payment for short term use of certain analgesics that currently require prior authorization.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients between the ages of 18 and 65 having one of three elective procedures as an outpatient. These procedures are associated with moderate to severe postoperative pain (anterior cruciate ligament reconstruction (knee), ankle ligament reconstruction (foot/ankle), or ligament reconstruction with tendon interposition (hand))
  • Patients should have operative risk category of American Society of Anesthesiologists (ASA) 1 or 2 .
  • Patients weighing between 70-100kg will be included to allow standardization of medication dosing

Exclusion criteria

  • Allergy to Study Medications
  • Previous History of Chronic Opioid Use
  • Patient Refusal to Participate
  • Known of Suspected History of Sleep Apnea
  • Known History of Chronic Pain Syndrome
  • Weight less than 70kg or greater than 100kg due to standardization of medication doses.
  • Revision Surgery
  • Inability to take study medications due to medication incompatibility or co-existing disease
  • Patients refusing or unable to receive US guided nerve block for postoperative pain
  • Patients unable to read and comprehend written consent document

Treatment and study plan

Celecoxib

Drug

Celecoxib 100mg

Other names: Celebrex

Acetaminophen

Drug

Acetaminophen 325mg

Other names: Paracetamol

Pregabalin

Drug

Pregabalin 50 mg

Other names: Lyrica

Oxycodone

Drug

oxycodone 5-10 mg

Other names: Xtampza ER, Oxaydo, Roxicodone

Percocet

Drug

Percocet (oxycodone 5mg/acetaminophen 325 mg)

Other names: Oxycodone / Paracetamol

Primary outcomes

  1. Amount of Pain Experienced

    Time frame: Cumulative every day after 6 days post-operative

    Pain as measured by a 0-10 Visual Analog Scale (VAS) pain scale, where "0" is the lowest score and "10" is the highest score. For example, 10 would be severe pain and 0 would be none. Cumulative scores were the total scores over 6 days and were expressed with the absolute totals with range. No subscales were used. Cumulative scores represent the absolute sum of each data point for 6 days. The total cumulative range for pain is 0-60.

Secondary outcomes

  1. Amount of Nausea Experienced

    Time frame: Cumulative every day after 6 days post-operative

    Nausea as measured by a 0-10 Visual Analog Scale (VAS) nausea scale, where "0" is the lowest score and "10" is the highest score. For example, 10 would be severe nausea and 0 would be none. Cumulative scores were the total scores over 6 days and were expressed with the absolute totals with range. No subscales were used. Cumulative scores represent the absolute sum of each data point for 6 days. The total cumulative range for nausea is 0-60.

  2. Amount of Itching Experienced

    Time frame: Cumulative every day after 6 days post-operative

    Itching as measured by a 0-10 Visual Analog Scale (VAS) itching scale, where "0" is the lowest score and "10" is the highest score. For example, 10 would be severe itching and 0 would be none. Cumulative scores were the total scores over 6 days and were expressed with the absolute totals with range. No subscales were used. Cumulative scores represent the absolute sum of each data point for 6 days. The total cumulative range for itching is 0-60.

  3. Amount of Oxycodone Used

    Time frame: Cumulative every day after 6 days post-operative

    Oxycodone use, measured by number of 5-mg tablets as standard dose

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Registry information

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Jul 11, 2019
Registry last updated
Jul 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.